Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2014; 03(03): 182-184
DOI: 10.4103/2278-330X.136811
Drug Review

Tolvaptan

Bharath Rangarajan
Department of Medical Oncology, Mazumdar Shaw Cancer Center, Bengaluru, Karnataka
,
Vineetha Binoy
Department of Medical Oncology, Mazumdar Shaw Cancer Center, Bengaluru, Karnataka
,
Sachin Sharatchandra Hingmire
Department of Medical Oncology, Deenanath Mangeshkar Hospital, Pune
,
Vanita Noronha
Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, Maharashtra
› Author Affiliations Source of Support: Nill.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Hyponatremia is a common and often under-recogonised clinical problem in oncologic practice. The recogonition of the cause of hyponatremia and initiation of appropriate and timely intervention can prevent morbidity and improve treatment tolerance. This drug review aims at discussing the currently approved oral vaptanagent Tolvaptan. Vaptans including Tolvaptan act as "aquaretic" agents cousing excretion of water while retaining the sodium. Administration of this agent for prescribed periods result in improvement of serum sodium levels. The drug can be used in many clinical situations resulting in hyponatremia including congestive heart failure, cirrhosis and syndrome of inappropriate ADH secretion (SIADH) including SIADH related to malignancies.

Key words

Hyponatremia - tolvaptan - syndrome of inappropriate anti-diuretic hormone - paraneoplastic syndrome


Publication History

Article published online:
31 December 2020

© 2014. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Hoorn EJ, van der Lubbe N, Zietse R. SIADH and hyponatraemia: Why does it matter? NDT Plus 2009;2 Suppl 3:iii5-11.
  • 2 Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006;119:71.e1-8.
  • 3 Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: The vaptans. Lancet 2008;371:1624-32.
  • 4 Hoorn EJ, Zietse R. Vasopressin-receptor antagonists. Future Cardiol 2010;6:523-34.
  • 5 Aditya S, Rattan A. Vaptans: A new option in the management of hyponatremia. Int J Appl Basic Med Res 2012;2:77-83.
  • 6 Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs 2007;67:847-58.
  • 7 Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-112.
  • 8 Reilly T, Chavez B. Tolvaptan (Samsca) for hyponatremia: Is it worth its salt? Phys Ther 2009;34:543-7.
  • 9 Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010;21:705-12.
  • 10 Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 2007;297:1319-31.
  • 11 Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA 2007;297:1332-43.
  • 12 Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O′Connor CM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: An analysis from the OPTIMIZE-HF registry. Eur Heart J 2007;28:980-8.
  • 13 Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Piña IL, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the escape trial. Arch Intern Med 2007;167:1998-2005.
  • 14 Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407-18.
  • 15 Vaidya C, Ho W, Freda BJ. Management of hyponatremia: Providing treatment and avoiding harm. Cleve Clin J Med 2010;77:715-26.